A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half. What doesn’t it ...

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

Weight-loss and diabetes drugs like Ozempic and Mounjaro could be used to treat drug and alcohol addiction in the future — ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.